36 results on '"Pinzello G"'
Search Results
2. HCV E1E 2‐ MF 59vaccine in chronic hepatitis C patients treated with PEG ‐ IFN α2a and R ibavirin: a randomized controlled trial
3. 755 5-YEAR ENTECAVIR TREATMENT IN NUC-NAÏVE, FIELD-PRACTICE PATIENTS WITH CHRONIC HEPATITIS B SHOWED EXCELLENT VIRAL SUPPRESSION AND SAFETY PROFILE BUT NO PREVENTION OF HCC IN CIRRHOTICS
4. T-12 Tenofovir suppressed viral suppression in most field practice, treatment-naïve patients with CHB followed for 3 years in a multicenter European study
5. T-11 5-year entecavir in NUC-naïve, field-practice patients with CHB showed excellent viral suppression and safety but no prevention of HCC
6. 522 MAINTAINED VIRAL SUPPRESSION AND EXCELLENT SAFETY PROFILE OF ENTECAVIR MONOTHERAPY IN 418 NUC-NAÏVE PATIENTS WITH CHRONIC HEPATITIS B: A 4-YEAR FIELD PRACTICE, MULTICENTER STUDY
7. 695 PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WITHOUT CIRRHOSIS HAD OFTEN UNDETECTABLE RISK FACTORS AND A MORE ADVANCED DISEASE AT DIAGNOSIS
8. 525 TENOFOVIR MONOTHERAPY FOR NAÏVE PATIENTS WITH CHRONIC HEPATITIS B: A MULTICENTER EUROPEAN STUDY IN CLINICAL PRACTICE IN 302 PATIENTS FOLLOWED FOR 30 MONTHS
9. P.15.2 ENTECAVIR MONOTHERAPY IN 418 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B FROM FIELD PRACTICE: HIGH EFFICACY AND FAVORABLE SAFETY PROFILE OVER 3 YEARS OF TREATMENT
10. OC.07.1 2-YEAR EFFECTIVENESS AND SAFETY OF TENOFOVIR IN 302 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B: A MULTICENTER EUROPEAN STUDY IN CLINICAL PRACTICE
11. T-8 Entecavir monotherapy in 418 NUC-naive patients with chronic hepatitis B from field practice: high efficacy and favorable safety profile over 3 years of treatment
12. T-9 2-year effectiveness and safety of tenofovir in 302 NUC-naive patients with chronic hepatitis B: a multicenter European study in clinical practice
13. OC.09.2: MAINTAINED LONG-TERM SUPPRESSION OF HBV REPLICATION IN NUC-NAÏVE PATIENTS WITH CHRONIC HEPATITIS B TREATED WITH ETV MONOTHERAPY IN FIELD PRACTICE: THE ITALIAN MULTICENTER EXPERIENCE
14. 731 EFFECTIVENESS AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE IN FIELD PRACTICE: A MULTICENTER EUROPEAN COHORT STUDY OF 302 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B
15. P.1.48: EFFECTIVENESS AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE IN FIELD PRACTICE: A MULTICENTER EUROPEAN COHORT STUDY OF 737 PATIENTS WITH CHRONIC HEPATITIS B
16. F-34 Maintained long-term suppression of HBV replication in NUC-naïve patients with chronic hepatitis B treated with ETV monotherapy in field practice: The Italian multicenter experience
17. F-36 Effectiveness and safety of tenofovir disoproxil fumarate in field practice: A multicenter European cohort study of 737 patients with chronic hepatitis B
18. 602 THE CANDIDATE HCV E1E2MF59 VACCINE IS SAFE IN CHRONIC HEPATITIS C PATIENTS AND ACCELLERATES THE SECOND PHASE VIRAL DECLINE UPON PRIMARY RESPONSE TO PEG-INTERFERON-2A/RIBAVIRIN THERAPY
19. 499 GENOTYPE 2 AND 3 RECCURENT HEPATITIS C AFTER LIVER TRANSPLANTATION: EXCELLENT RESULTS WITH SUBOPTIMAL DOSES OF ANTIVIRAL THERAPY
20. Genotypes 2 and 3 recurrent hepatitis C after liver transplantation: Excellent results with suboptimal doses of antiviral therapy
21. The candidate HCV E1E2MF59 vaccine enhances 2nd phase viral decline in responders to PEG-IFN/ribavirin
22. 820 HCV GENOTYPE 4 IN SUBJECTS UNDERGOING ANTIVIRAL TREATMENT IN ITALY
23. [141] LONG TERM FOLLOW-UP OF LIVER TRANSPLANTATION (OLT) FOR CHOLESTATIC AND AUTOIMMUNE END STAGE LIVER DISEASES
24. [752] DRUG-INDUCED HEPATITIS IN PATIENTS HOSPITALIZED FOR ABNORMAL LIVER TESTS
25. Drug-induced hepatitis in patients hospitalized for abnormal liver tests
26. Lack of a strong association between HLA class II, tumour necrosis factor and transporter associated with antigen processing gene polymorphisms and virological response to alpha-interferon treatment in patients with chronic hepatitis C
27. 110 No recurrence in patients transplanted for YMDD genotypic mutations using pre-emptive lamivudine followed by combination prophylaxis
28. Chronic hepatitis C (CH-C) genotype 1: An independent, multicenter RCT comparing PEG-IFN ALFA-2B 12KD plus ribavirin (RBV) and IFN ALFA-2B plus (RBV) in naive patients
29. 199Early ribavirin treatment and avoidance of steroids in HCV positive liver transplant candidates: Preliminary report of a prospective randomized trial
30. Early ribavirin treatment and avoidance of steroids in HCV positiveliver transplant candidates: Preliminary report of a prospectiverandomized trial
31. Acute liver failure in sickle cell/β-thal disease solved by intensive transfuslonal regimen
32. Immunoblotting as a confirmatory test for antimitochondrial antibodies in primary biliary cirrhosis.
33. Serum hepatitis C virus (HCV)-RNA and response to alpha-interferon in anti-HCV positive chronic hepatitis
34. Detection and characterization of antibodies to polymerized human serum albumin (AAA) by ELISA
35. Laxative Consumption in Chronic Nonorganic Constipation
36. The prognostic value of thyroid function tests in predominantly non-alcoholic cirrhotic patients: a prospective investigation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.